Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Devazepide

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Devazepide
Clinical data
ATC code
  • none
Identifiers
  • N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.208.547Edit this at Wikidata
Chemical and physical data
FormulaC25H20N4O2
Molar mass408.461 g·mol−1
3D model (JSmol)
  • O=C(c2cc1ccccc1[nH]2)N[C@H]3/N=C(\c4ccccc4N(C3=O)C)c5ccccc5
  • InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1 ☒N
  • Key:NFHRQQKPEBFUJK-HSZRJFAPSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Devazepide[1] (L-364,718,MK-329) isbenzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity forGABAA receptors and instead acting as anCCKAreceptor antagonist.[2] It increases appetite and accelerates gastric emptying,[3][4] and has been suggested as a potential treatment for a variety of gastrointestinal problems includingdyspepsia,gastroparesis andgastric reflux.[5] It is also widely used in scientific research into the CCKA receptor.[6][7]

Synthesis

[edit]

Devazepide is synthesised in a similar manner to other benzodiazepines.[8][9]

See also

[edit]

References

[edit]
  1. ^US 4820834, Evans, Ben E.; Freidinger, Roger M. & Bock, Mark G., "Benzodiazepine analogs", published 1989-04-11, assigned toMerck & Co. Inc. 
  2. ^Hill DR, Woodruff GN (September 1990). "Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260".Brain Research.526 (2):276–83.doi:10.1016/0006-8993(90)91232-6.PMID 2257485.S2CID 23851131.
  3. ^Cooper SJ, Dourish CT (December 1990). "Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding".Physiology & Behavior.48 (6):849–57.doi:10.1016/0031-9384(90)90239-z.PMID 1982361.S2CID 24850080.
  4. ^Cooper SJ, Dourish CT, Clifton PG (January 1992)."CCK antagonists and CCK-monoamine interactions in the control of satiety".The American Journal of Clinical Nutrition.55 (1 Suppl):291S–295S.doi:10.1093/ajcn/55.1.291s.PMID 1728842.
  5. ^Scarpignato C, Varga G, Corradi C (1993). "Effect of CCK and its antagonists on gastric emptying".Journal of Physiology, Paris.87 (5):291–300.doi:10.1016/0928-4257(93)90035-r.PMID 8298606.S2CID 23725376.
  6. ^Weller A (July 2006). "The ontogeny of postingestive inhibitory stimuli: examining the role of CCK".Developmental Psychobiology.48 (5):368–79.doi:10.1002/dev.20148.PMID 16770766.
  7. ^Savastano DM, Covasa M (October 2007). "Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors".Physiology & Behavior.92 (3):434–42.doi:10.1016/j.physbeh.2007.04.017.PMID 17531277.S2CID 5566756.
  8. ^Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, et al. (December 1988). "Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists".Journal of Medicinal Chemistry.31 (12):2235–46.doi:10.1021/jm00120a002.PMID 2848124.
  9. ^EP 1492540, Jackson, Karen, "The use of devazepide as analgesic agent", published 2005-01-05, assigned to ML Laboratories plc 
1,4-Benzodiazepines
1,5-Benzodiazepines
2,3-Benzodiazepines*
Triazolobenzodiazepines
Imidazobenzodiazepines
Oxazolobenzodiazepines
Thienodiazepines
Thienotriazolodiazepines
Thienobenzodiazepines*
Pyridodiazepines
Pyridotriazolodiazepines
Pyrazolodiazepines
Pyrrolodiazepines
Tetrahydroisoquinobenzodiazepines
Pyrrolobenzodiazepines*
Benzodiazepine prodrugs
* atypical activity profile (notGABAA receptor ligands)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Devazepide&oldid=1329562863"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp